# Josep Maria Auge Fradera

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 56 papers | 2,282 citations | 236925 25 h-index | 214800 47 g-index |
| 58 all docs | 58 docs citations | 58 times ranked | 3419 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis. Tumor Biology, 2003, 24, 209-218. | 1.8 | 233 |
| 2 | Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases. Clinical Chemistry, 2011, 57, 1534-1544. | 3.2 | 167 |
| 3 | Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 427-437. | 5.6 | 139 |
| 4 | HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biology, 2011, 32, 1087-1095. | 1.8 | 133 |
| 5 | ProGRP: a new biomarker for small cell lung cancer. Clinical Biochemistry, 2004, 37, 505-511. | 1.9 | 118 |
| 6 | Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor Biology, 2008, 29, 371-380. | 1.8 | 107 |
| 7 | Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with Histology. Tumor Biology, 2009, 30, 121-129. | 1.8 | 94 |
| 8 | Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program. Gastroenterology, 2014, 147, 628-636.e1. | 1.3 | 94 |
| 9 | Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. International Journal of Cancer, 2007, 121, 1066-1071. | 5.1 | 90 |
| 10 | Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomarkers, 2010, 6, 163-178. | 1.7 | 75 |
| 11 | Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. Clinical Chemistry, 2010, 56, 1148-1157. | 3.2 | 70 |
| 12 | The Role of MMP7 and Its Cross-Talk with the FAS/FASL System during the Acquisition of Chemoresistance to Oxaliplatin. PLoS ONE, 2009, 4, e4728. | 2.5 | 68 |
| 13 | Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biology, 2010, 31, 171-180. | 1.8 | 61 |
| 14 | Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumor Biology, 2012, 33, 463-474. | 1.8 | 52 |
| 15 | PCA3 in the detection and management of early prostate cancer. Tumor Biology, 2013, 34, 1337-1347. | 1.8 | 48 |
| 16 | Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases. Tumor Biology, 2004, 25, 56-61. | 1.8 | 44 |
| 17 | Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1347-55. | 2.3 | 43 |
| 18 | CA 19â€“9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumor Biology, 2012, 33, 799-807. | 1.8 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Reassessment colonoscopy to diagnose serrated polyposis syndrome in a colorectal cancer screening population. Endoscopy, 2017, 49, 44-53. | 1.8 | 35 |
| 20 | Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency. Anticancer Research, 2018, 38, 5883-5888. | 1.1 | 35 |
| 21 | Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1391-1398. | 0.8 | 31 |
| 22 | Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. Clinical Chemistry and Laboratory Medicine, 2016, 54, 125-32. | 2.3 | 29 |
| 23 | Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. Endocrine-Related Cancer, 2009, 16, 311-317. | 3.1 | 28 |
| 24 | The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10Î¼g/L. Clinica Chimica Acta, 2014, 436, 303-307. | 1.1 | 28 |
| 25 | Circulating levels of HER-2/neu oncoprotein in breast cancer. Clinical Chemistry and Laboratory Medicine, 2012, 50, 5-21. | 2.3 | 27 |
| 26 | Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona. BMC Medical Genetics, 2013, 14, 26. | 2.1 | 24 |
| 27 | Variability of assay methods for total and free PSA after WHO standardization. Tumor Biology, 2014, 35, 1867-1873. | 1.8 | 24 |
| 28 | Association between socioeconomic deprivation and colorectal cancer screening outcomes: Low uptake rates among the most and least deprived people. PLoS ONE, 2017, 12, e0179864. | 2.5 | 24 |
| 29 | Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Digestive and Liver Disease, 2016, 48, 542-551. | 0.9 | 23 |
| 30 | Contribution of CSF biomarkers to earlyâ€onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. Human Brain Mapping, 2020, 41, 2004-2013. | 3.6 | 22 |
| 31 | Serum Matrilysin Levels Predict Outcome in Curatively Resected Colorectal Cancer Patients. Annals of Surgical Oncology, 2009, 16, 1412-1420. | 1.5 | 21 |
| 32 | Changes in FIT values below the threshold of positivity and short-term risk of advanced colorectal neoplasia: Results from a population-based cancer screening program. European Journal of Cancer, 2019, 107, 53-59. | 2.8 | 21 |
| 33 | Serum Vascular Endothelial Growth Factor as a Predictive Factor in Metronomic (Weekly) Paclitaxel Treatment for Advanced Head and Neck Cancer. JAMA Otolaryngology, 2007, 133, 1143. | 1.2 | 20 |
| 34 | Clinical applicability of diagnostic biomarkers in earlyâ€onset cognitive impairment. European Journal of Neurology, 2019, 26, 1098-1104. | 3.3 | 20 |
| 35 | Serum Protein S-100 Predicts Clinical Outcome in Patients with Melanoma Treated with Adjuvant Interferon â€“ Comparison with Tyrosinase RT-PCR. Oncology, 2005, 68, 341-349. | 1.9 | 18 |
| 36 | Faecal immunochemical tests for haemoglobin: Analytical challenges and potential solutions. Clinica Chimica Acta, 2021, 517, 60-65. | 1.1 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Colorectal cancer after negative colonoscopy in fecal immunochemical test-positive participants from a colorectal cancer screening program. Endoscopy International Open, 2018, 06, E1140-E1148. | 1.8 | 16 |
| 38 | S-100beta and MIA in advanced melanoma in relation to prognostic factors. Anticancer Research, 2005, 25, 1779-82. | 1.1 | 16 |
| 39 | Prognostic Implications of Protein S-100β Serum Levels in the Clinical Outcome of High-Risk Melanoma Patients. Tumor Biology, 2007, 28, 264-272. | 1.8 | 15 |
| 40 | Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the AccessÂ® GI Monitor assay on the UniCelÂ® DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine, 2008, 46, 600-11. | 2.3 | 15 |
| 41 | An evaluation of the SENTiFIT 270 analyser for quantitation of faecal haemoglobin in the investigation of patients with suspected colorectal cancer. Clinical Chemistry and Laboratory Medicine, 2018, 56, 625-633. | 2.3 | 11 |
| 42 | Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the AccessÂ® BR Monitor assay on the UniCelÂ® DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine, 2008, 46, 612-22. | 2.3 | 10 |
| 43 | Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the AccessÂ® OV Monitor assay on the UniCelÂ® DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine, 2008, 46, 588-99. | 2.3 | 10 |
| 44 | Faecal haemoglobin concentrations do vary across geography as well as with age and sex: ramifications for colorectal cancer screening. Clinical Chemistry and Laboratory Medicine, 2015, 53, e235-7. | 2.3 | 10 |
| 45 | Utility of proGRP as a tumor marker in the medullary thyroid carcinoma. Clinical Chemistry and Laboratory Medicine, 2017, 55, 441-446. | 2.3 | 10 |
| 46 | Analytical and clinical evaluation of DiaSorin LiaisonÂ® Calprotectin fecal assay adapted for serum samples. Journal of Clinical Laboratory Analysis, 2022, 36, e24258. | 2.1 | 6 |
| 47 | Colonic Penetration after Kugel Patch Inguinal Hernia Repair. Japanese Journal of Gastroenterological Surgery, 2010, 43, 90-94. | 0.1 | 4 |
| 48 | Evaluating the Potential of Polygenic Risk Score to Improve Colorectal Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1305-1312. | 2.5 | 4 |
| 49 | Mo1701 Gastrointestinal Events After a Negative Colonoscopy in FIT-Positive Participants in an Organized, Population-Based Colorectal Cancer Screening Program. Gastroenterology, 2016, 150, S756. | 1.3 | 1 |
| 50 | Impacto de una intervenciÃ³n de AtenciÃ³n Primaria en el programa de detecciÃ³n precoz de cÃ¡ncer colorrectal. GastroenterologÃa Y HepatologÃa, 2019, 42, 351-361. | 0.5 | 1 |
| 51 | Serum vascular endothelial growth factor as prognostic factor in metronomic weekly paclitaxel treatment for patients with advanced head and neck cancer refractoryto platinum-based chemotherapy. Radiotherapy and Oncology, 2007, 82, S33. | 0.6 | 0 |
| 52 | Correlation of matrilysin levels and IGF-1/IGFBP-3 ratio with acquired chemo-resistance in advanced colorectal cancer (ACRC). Journal of Clinical Oncology, 2008, 26, 15023-15023. | 1.6 | 0 |
| 53 | Pharmacodynamic study of soluble FAS (sFAS) and FASL (sFASL), in patients (pts) with advanced colorectal cancer (ACRC) after irinotecan and cetuximab treatment in third-line therapy: Results of HCB-05â€“01 trial. Journal of Clinical Oncology, 2008, 26, 22046-22046. | 1.6 | 0 |
| 54 | EvaluaciÃ³n del ensayo enhaced estradiol (eE2) en el analizador Atellica IM 1600 de Siemens. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, . | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Performance evaluation of Siemens Atellica enhanced estradiol assay. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, . | 0.2 | 0 |
| 56 | Agreement of amyloid PET and CSF biomarkers in a clinical cohort. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |